HZHong Zhu

Hong Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong Zhu has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Hongxiao Jia

    Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100069, China

    6 shared publications
  • Sisi Zheng

    Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders and National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University;

    6 shared publications
  • Yanzhe Ning

    Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100069, China

    3 shared publications
  • Dongqing Yin

    The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China, China

    2 shared publications
  • Sitong Feng

    Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, People’s Republic of China

    2 shared publications
  • Anquan Zhao

    Tangshan Fifth Hospital, Tangshan, Hebei 063005, China

    1 shared publication

Latest Publications

  • Clinical Improvement Following Multimodal Treatment in Depersonalization-Derealization Disorder: A Case Report

    by Qiyu Zheng, Yan Zhao, Sisi Zheng, Hong Zhu

    Depersonalization-derealization disorder (DPD) is characterized by persistent or recurrent detachment from the self or the surrounding environment with preserved reality testing. Because established treatment evidence remains limited, individualized therapeutic strategies are often required. This report describes a patient with derealization, emotional blunting, poor memory, slowed reactions, and impaired attention. Psychiatric evaluation showed marked depersonalization-derealization symptoms, with a Cambridge Depersonalization Scale (CDS) score of 147, a 24-item Hamilton Depression (HAMD-24) Rating Scale score of 8, a 14-item Hamilton Anxiety (HAMA-14) Rating Scale score of 5, and a MATRICS Consensus Cognitive Battery (MCCB) composite T-score of 49. The patient underwent a stepwise multimodal treatment approach that included transcranial direct current stimulation, pharmacotherapy with duloxetine and tandospirone, duloxetine dose optimization, lamotrigine augmentation and titration, and later gradual medication tapering under follow-up monitoring. Clinical improvement was observed during longitudinal assessment. This case highlights the practical value of a monitored, sequential, and multimodal treatment strategy for a patient with DPD. Although the findings are limited to a single case, the observed temporal association between intervention and improvement provides a hypothesis-generating clinical observation and supports the need for systematic studies of multimodal treatment approaches in DPD.

  • Top Cited Papers
    Open Access

    Understanding psychiatrist readiness for AI: a study of access, self-efficacy, trust, and design expectations

    by Yue He, Francis Xiatian Zhang, Xiaxia Wu, Meng Fang, Sisi Zheng, Hong Zhu

    Background: Artificial intelligence (AI) is receiving growing attention in psychiatric practice, yet psychiatrists vary considerably in how they perceive its benefits, risks, and clinical usefulness. Successful implementation depends not only on technological performance but also on clinicians’ readiness, including their access to AI, confidence in using it, trust in its reliability, and expectations for its design. Evidence on these dimensions remains limited in China. Objective: This study examined Chinese psychiatrists’ readiness for AI across four dimensions—access, self-efficacy, trust, and design expectations—and explored variation across demographic and professional subgroups. Method: A cross-sectional online survey was distributed through the WeChat platform from March 20 to 22, 2025. Eligible participants were licensed psychiatrists engaged in clinical practice. A total of 134 valid responses were obtained from clinicians across diverse provinces, hospital tiers, and professional roles. Descriptive analyses and group comparisons were conducted. Results: Psychiatrists reported broad exposure to AI, though knowledge was largely acquired through informal rather than structured sources. Overall self-efficacy was moderate, with higher confidence observed among younger clinicians, male clinicians, and those who had received AI-related training. Trust in AI was generally positive, and department heads expressed especially strong confidence in its future role. Across subgroups, psychiatrists consistently prioritized AI applications that reduce administrative and documentation burden, while expressing lower expectations for AI use in communication, assessment, or psychotherapy. Conclusion: Chinese psychiatrists demonstrated cautious optimism and moderate readiness for AI. Limited access to formal training and subgroup differences in confidence highlight the need for targeted capacity-building. The strong preference for documentation-support tools underscores the importance of designing AI systems that integrate smoothly into clinical workflows while preserving the human-centered nature of psychiatric care.


  • The Treatment of Depersonalization-Derealization Disorder: A Systematic Review

    by Sici Wang, Sisi Zheng, Francis Xiaitan Zhang, Rui Ma, Sitong Feng, Mingkang Song, Hong Zhu, Hongxiao Jia

    Depersonalization-derealization disorder (DPD) is characterized by persistent or recurrent experiences of detachment from oneself and surroundings, as well as a sense of unreality. Considering the inadequacy of current research on treatment, we performed a systematic review of the available pharmacotherapies, neuromodulations, and psychotherapies for DPD. The systematic review protocol was based on PRISMA 2020 guidelines and pre-registered. The PubMed, Web of Science, PsycINFO, Embase, the Cochrane Library, Scopus, and ScienceDirect databases were searched from inception to June 2021. All treatments for DPD and all study types, including controlled and observational studies as well as case reports, were assessed. Of the identified 17,540 studies, 41 studies (four randomized controlled trials, one non-randomized controlled trial, 10 case series, and 26 case reports) involving 300 participants met the eligibility criteria. We identified 30 methods that have been applied independently or in combination to treat DPD since 1955. The quality of these studies was considered. The relationship between individual differences, such as symptoms, comorbidities, history, and duration since onset, and treatment effects was explored. The results suggest that a series of treatments, such as pharmacotherapies, neuromodulation, and psychotherapies, could be considered in combination. However, the quality and quantity of studies were generally low considering the high prevalence of DPD. The review concludes with suggestions for future research and an urgent call for more high-quality research.


  • Open Access

    Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study

    by Ling Hou, Ke Huang, Chunxiu Gong, Feihong Luo, Haiyan Wei, Liyang Liang, Hongwei Du, Jianping Zhang, Yan Zhong, Ruimin Chen, et al.

    Context The evidence of long-term polyethylene glycol recombinant human GH (PEG-rhGH) in pediatric GH deficiency (GHD) is limited. Objective This study aimed to examine the effectiveness and safety of long-term PEG-rhGH in children with GHD in the real world, as well as to examine the effects of dose on patient outcomes. Design A prospective, observational, posttrial study (NCT03290235). Setting, participants and intervention Children with GHD were enrolled from 81 centers in China in 4 individual clinical trials and received weekly 0.2 mg/kg/wk (high-dose) or 0.1 to P < 0.0001), with a mean change of 0.53 ± 0.30, 0.89 ± 0.48, 1.35 ± 0.63, 1.63 ± 0.75 at 6 months, 12 months, 24 months, and 36 months, respectively. In addition, the changes in Ht SDS from baseline were significantly improved in the high-dose subgroup compared with the low-dose subgroup at 6, 12, 24, and 36 months after treatment (all P < 0.05). A total of 12 (1.03%) patients developed serious adverse events. There was no serious adverse event related to the treatment, and no AEs leading to treatment discontinuation or death occurred. Conclusions PEG-rhGH showed long-term effectiveness and safety in treating children with GHD. Both dose subgroups showed promising outcomes, whereas PEG-rhGH 0.2 mg/kg/wk might show additional benefit.


  • Open Access

    An Experimental Study of Subliminal Self-Face Processing in Depersonalization–Derealization Disorder

    by Shanshan Liu, Yuan Jia, Sisi Zheng, Sitong Feng, Hong Zhu, Rui Wang, Hongxiao Jia

    The self-perception or self-experience of patients with depersonalization/derealization disorder (DPD) is altered, leading to a profound disruption in self-awareness. The main aim of the study is to explore the characteristics of subliminal self-face processing in DPD patients. To our knowledge, this is the first experimental study that has measured and evaluated subliminal self-processing in DPD. To better understand this, we examined the ability of patients with DPD and healthy controls (HC) to identify pictures of faces using an experimental paradigm of breaking continuous flash suppression. There were 23 DPD outpatients from Beijing Anding Hospital, Capital Medical University and 23 matched HC who participated in this experiment. The time needed for a face to break into awareness was taken as the measure of participants’ subliminal processing of that face. The results indicated that there were significant differences between the DPD patients and HC in subliminal reaction times to different faces. Under experimental conditions, the average reaction response of self-face recognition in the HC group was significantly faster than for a famous face. However, this difference was not observed in DPD patients, which means that DPD patients did not show the processing advantage of their own faces as did the HC. The results suggest a deficit in subliminal self-face processing in DPD.


  • Open Access

    Potential Targets for Noninvasive Brain Stimulation on Depersonalization-Derealization Disorder

    by Sisi Zheng, Nan Song, Sici Wang, Yanzhe Ning, Hong Zhu, Mingkang Song, Yuan Jia, Hongxiao Jia

    Introduction: Non-invasive brain stimulation seems to be beneficial for DPD patients. However, the sites used in previous studies were empirical. Exploring new stimulation locations via functional magnetic resonance imaging may improve the efficacy. Objectives: The objective was to find potential locations for non-invasive brain stimulation on the depersonalization-derealization disorder. Methods: We explored the potential brain surface regions from three pipelines: pipeline 1: activation likelihood estimation meta-analysis (five studies with 36 foci included); pipeline 2: functional connectivity analysis based on DPD-network (76 subjects included); and pipeline 3: functional connectivity analysis based on DPD regions of interest from the meta-analysis. Potential targets were the 10–20 system coordinates for brain surface regions. Results: We identified several potential brain surface regions, including the bilateral medial prefrontal cortex, dorsal lateral prefrontal cortex, superior parietal gyrus, superior temporal gyrus, and right ventrolateral prefrontal cortex as potential sites. Conclusion: Our findings of the potential stimulation targets might help clinicians optimize the application of non-invasive brain stimulation therapy in individuals with DPD.


  • Open Access

    Effects of Jie Yu Wan on Generalized Anxiety Disorder: A Randomized Clinical Trial

    by Xue Li, Sisi Zheng, Sitong Feng, Rui Ma, Yuan Jia, Anquan Zhao, Dan Wei, Hua Guo, Na Duan, Ying Ding, et al.

    Objective. To systematically assess the clinical efficacy of the Jie Yu Wan (JYW) formula in treating generalized anxiety disorder (GAD). Methods. A multicenter, prospective, double-blind, double-dummy, randomized controlled trial (RCT) was conducted at four hospitals in China. A total of one hundred thirty-three patients with GAD were enrolled from 2017 to 2019. This study aimed to evaluate the effects of a Traditional Chinese Medicine (TCM) JYW formula on GAD at eight weeks, with the use of Buspirone as the comparator. A stepwise dosing protocol was used (JYW: high dose 24 g/day, low dose 12 g/day; Buspirone: high dose 30 mg/day, low dose 15 mg/day) and the dose was adjusted depending on whether the treatment response of Hamilton Anxiety Scale (HAMA) score was less than or equal to 25% after one week. The primary outcome was a change in total score on the HAMA. The secondary outcomes included the Hamilton Depression Scale (HAMD), Clinical Global Impression (CGI) scale, and TCM Syndrome Scale. Adverse events were recorded using the Treatment Emergent Symptom Scale (TESS). Assessments were conducted at the baseline and 1, 2, 4, and 8 weeks. Results. A total of one hundred thirty-three participants were randomly assigned to the JYW group (n = 66) and the Buspirone group (n = 67). One hundred twenty-one patients (91%) completed at least one follow-up session. There were no significant differences between the two groups in terms of gender, age, disease course, HAMA, HAMD, CGI, and TCM Syndrome Scale scores at baseline (all ). Repeated-measures analysis of variance revealed statistically significant time effects for the HAMA ( ), HAMD (P = 0.018), and CGI ( ) in both groups. Sensitivity analyses supported the credibility of the main results ( ). The group effect was not significant for the HAMA ( ), HAMD ( ), CGI ( ), and TCM Syndrome Scale ( ). Furthermore, there were no significant interaction effects between time and group in terms of the HAMA ( ), HAMD ( ), CGI ( ), and TCM Syndrome Scale ( ). After one week, 53 patients (80%) of the JYW group and 52 patients (78%) of the Buspirone group were adjusted to high doses. The interaction effect between time, group, and the dose was determined by repeated measures ANOVA test, and the HAMA score served as the outcome measure. The interaction effect between time and dose was statistically significant ( ), which shows that high-dose JYW (24 g/day) was more effective in decreasing patients’ HAMA scores than low-dose JYW (12 g/day), and Buspirone had the same effect, which means that high-dose Buspirone (30 mg/day) was more effective than low dose. (15 mg/day). Conclusions. The conclusion of this study supports that JYW and Buspirone can effectively alleviate the anxiety symptoms of GAD patients, which are both effective and safe for treatment of mild to moderate GAD. Besides, high-dose JYW or Buspirone are more effective than low-dose, which is of great importance in assisting clinical medication choice.


  • Open Access

    Disrupted Resting-State Functional Connectivity between the Dorsal Attention, Default Mode, and Frontoparietal Networks in Nonorganic Gastrointestinal Disorder Patients with Spleen Deficiency Syndrome

    by Yanzhe Ning, Wenbin Jia, Dongqing Yin, Xinzi Liu, Hong Zhu, Hongxiao Jia

    Introduction. Spleen deficiency syndrome (SDS), a common clinical syndrome of traditional Chinese medicine, is manifested with digestive symptoms and cognitive impairments. However, the cognitive neural mechanism in brain networks of SDS still remained unclear. Our aim was to investigate the changes between the default mode, dorsal attention, and frontoparietal networks in SDS. Methods. Twenty nonorganic gastrointestinal disorder (NOGD) patients with SDS and eighteen healthy controls were enrolled to attend functional magnetic resonance imaging scan and participated a continuous performance test (CPT) before scanning. Results. Compared with healthy controls, NOGD patients with SDS showed the significantly increased functional connectivity (FC) between dorsal attention network (DAN) and left frontal-parietal control network (LFPN) and significantly decreased FC between LFPN and default mode network (DMN). The functional network connectivity analysis showed positive correlation coefficients between the DAN and LFPN and DAN and DMN as well as negative correlation between LFPN and DMN in NOGD patients with SDS compared with healthy controls. Correlation analysis revealed that the increased FC between LFPN and DAN was positively correlated with 4-digitnumber reaction time mean (RTM) and 3-digitnumber RTM. Conclusion. Our study may provide novel insights into the relationship among the DMN, DAN, and FPN in NOGD patients with SDS to deepen our understanding of the neuropsychological mechanisms of SDS.


  • Open Access

    Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial

    by Pei Chen, Hong Zhu, Yanzhe Ning, Dongqing Yin, Hongxiao Jia

    Background: Generalized anxiety disorder (GAD) is a persistent and common mental disorder that entails significant impairments in role functioning and quality of life. Currently available effective interventions include psychological therapies, self-help approaches, and pharmacological treatments, which do not quite meet clinical needs, and the ideal anxiolytic is still being sought. Shu-gan-qing-re (SGQR) formula, a Chinese patent medicine, has been well received by patients with GAD in Chinese clinical practice for years. The present prospective, double-blind, double-dummy, randomized controlled trial is designed to investigate the efficacy and safety of SGQR formula for GAD. Methods/design: A total of 200 eligible participants will be recruited from four hospitals in different parts of China. They will be randomly assigned to either the study group or the control group in a ratio of 1:1. Participants allocated to the study group will receive SGQR formula and buspirone placebo, while buspirone and SGQR placebo will be applied in the control group. Six scheduled visits will be conducted over the course of 8 weeks. Outcome measurements include Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale-17 (HAMD-17), Clinical Global Impression-Improvement Scale (CGI-I), Traditional Chinese Medicine Syndrome Scale for GAD, and pro-inflammatory cytokine tests: interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha. Adverse reactions will be evaluated by using the Treatment Emergent Symptom Scale (TESS). Safety outcomes and adverse events will also be recorded. Discussion: The study will provide scientific and objective assessments for the efficacy and safety of SGQR formula for patients with GAD, hopefully offering clinicians an alternative approach to GAD. Trial registration: Chinese Clinical Trial Registry, ID: ChiCTR-IPR-17013058. Registered on October 20, 2017.